Bayer collaborates with Pharmaron to develop new molecular entities for veterinary medicines

New Delhi: Bayer and Pharmaron have entered into a global collaboration agreement to develop new molecular entities for veterinary medicines.

Under the collaboration, Bayer will fully leverage Pharmaron’s Chemistry, Manufacturing and Controls (CMC) service platform. This will include drug substance and drug product manufacturing to support Bayer’s research, development and commercialization needs. Financial terms were not disclosed.

In its recent release, Bayer said that the company and Pharmaron have agreed to jointly develop new molecular entities. Their goal is to provide veterinarians, pet owners and farmers with innovative therapies that address unmet medical needs of their animal patients. Pharmaron will provide state-of-the-art CMC capabilities and resources to accelerate the development of preclinical and clinical projects for Bayer Animal Health. Small molecules have always been the backbone of innovative drugs in veterinary medicines. The partnership between Bayer and Pharmaron will facilitate the exploration of the small molecule-based chemical space, aiming to offer a variety of future therapeutic options for diseases that still cannot be adequately treated today.

Also Read: Bayer, WHO collaborate to combat taeniasis, neurocystercosis

Commenting on the collaboration, Dr Douglas Hutchens, Bayer Animal Health’s Head of Drug Discovery, External Innovation & Chief Veterinary Officer, said, “Our collaboration is another example of how we realize our innovation strategy: By combining the know-how and capabilities from an industry-leading Contract Development & Manufacturing Organization like Pharmaron with high-quality innovation projects derived from Bayer’s research, we will reduce our time to market and increase our success rate to deliver our development portfolio to the market. We are constantly looking for innovative partners that enable us to bring our projects faster and improve the probability of success in the animal health sector.”

Dr Boliang Lou, Chairman and CEO of Pharmaron commented, “Pharmaron’s mission is to provide high-quality R&D and commercialization services to the life sciences industry. We are very excited to form a strategic partnership with Bayer Animal Health, a world-leading animal health company, to jointly develop innovative medicines for animals, by tapping into Pharmaron’s CMC platform. We will work together to advance innovative products with high quality and an accelerated timeline, from discovery through development to commercialization.”

Also Read: You cannot discontinue critical medicines without Prior Notice: NPPA tells Abbott, Bayer Zydus Pharma, Sanofi